A Phase II, Parallel Group, Randomized, Multicentre, Open Label Study to Compare the Pharmacokinetics of Tacrolimus in De Novo Pediatric Allograft Recipients Treated with an Advagraf or Prograf Based Immunosuppressive Regimen, Including a Long-Term Follow-Up
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 29 Sep 2017
At a glance
- Drugs Tacrolimus (Primary)
- Indications Transplant rejection
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Astellas Pharma Europe Ltd
- 19 Jul 2017 Planned End Date changed from 1 Nov 2025 to 1 May 2026.
- 19 Jul 2017 Planned primary completion date changed from 1 Nov 2025 to 1 May 2026.
- 06 Jul 2017 This trial has been completed in France according to European Clinical Trials Database record.